{"doi":"10.1101/2024.01.29.577876","title":"Cellular Modeling of CLN6 with IPSC-derived Neurons and Glia","abstract":"ABSTRACT Neuronal ceroid lipofuscinosis (NCL), type 6 (CLN6) is a neurodegenerative disorder associated with progressive neurodegeneration leading to dementia, seizures, and retinopathy. CLN6 encodes a resident-ER protein involved in trafficking lysosomal proteins to the Golgi. CLN6p deficiency results in lysosomal dysfunction and deposition of storage material comprised of Nile Red + lipids/proteolipids that include subunit C of the mitochondrial ATP synthase (SUBC). White matter involvement has been recently noted in several CLN6 animal models and several CLN6 subjects had neuroimaging was consistent with leukodystrophy. CLN6 patient-derived induced pluripotent stem cells (IPSCs) were generated from several of these subjects. IPSCs were differentiated into oligodendroglia or neurons using well-established small-molecule protocols. A doxycycline-inducible transgenic system expressing neurogenin-2 (the I3N-system) was also used to generate clonal IPSC-lines (I3N-IPSCs) that could be rapidly differentiated into neurons (I3N-neurons). All CLN6 IPSC-derived neural cell lines developed significant storage material, CLN6-I3N-neuron lines revealed significant Nile Red + and SUBC + storage within three and seven days of neuronal induction, respectively. CLN6-I3N-neurons had decreased tripeptidyl peptidase-1 activity, increased Golgi area, along with increased LAMP1 + in cell bodies and neurites. SUBC + signal co-localized with LAMP1 + signal. Bulk-transcriptomic evaluation of control- and CLN6-I3N-neurons identified >1300 differentially-expressed genes (DEGs) with Gene Ontogeny (GO) Enrichment and Canonical Pathway Analyses having significant changes in lysosomal, axonal, synaptic, and neuronal-apoptotic gene pathways. These findings indicate that CLN6-IPSCs and CLN6-I3N-IPSCs are appropriate cellular models for this disorder. These I3N-neuron models may be particularly valuable for developing therapeutic interventions with high-throughput drug screening assays and/or gene therapy.","journal":"bioRxiv (Cold Spring Harbor Laboratory)","year":2024,"id":487811,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9493,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1332059,"name":"Jaemin Kim","orcid":"0000-0003-0566-3930","position":1,"is_corresponding":false},{"id":1332455,"name":"Yogesh K. Kushwaha","orcid":null,"position":2,"is_corresponding":false},{"id":1048716,"name":"Alex Rajewski","orcid":"0000-0003-3475-1999","position":3,"is_corresponding":false},{"id":1332456,"name":"Fabian David Nonis","orcid":null,"position":4,"is_corresponding":false},{"id":555558,"name":"Chintda Santiskulvong","orcid":"0000-0002-4762-991X","position":5,"is_corresponding":false},{"id":313380,"name":"Serguei Bannykh","orcid":null,"position":6,"is_corresponding":false},{"id":1332457,"name":"Hiral Oza","orcid":null,"position":7,"is_corresponding":false},{"id":1332060,"name":"Hafiz Muhammad Umer Farooqi","orcid":"0000-0002-1735-5911","position":8,"is_corresponding":false},{"id":1332458,"name":"Madeline Babros","orcid":null,"position":9,"is_corresponding":false},{"id":916844,"name":"Christina Freeman","orcid":null,"position":10,"is_corresponding":false},{"id":1053131,"name":"Lucie Dupuis","orcid":"0000-0002-6068-8199","position":11,"is_corresponding":false},{"id":1332459,"name":"Saadat Mercimek-Andrews","orcid":null,"position":12,"is_corresponding":false},{"id":733474,"name":"Roberto Mendoza‐Londono","orcid":"0000-0003-3542-8106","position":13,"is_corresponding":false},{"id":672556,"name":"Catherine Bresee","orcid":"0000-0002-5710-4906","position":14,"is_corresponding":false},{"id":362136,"name":"David R. Adams","orcid":"0000-0002-6660-1242","position":15,"is_corresponding":false},{"id":70653,"name":"Cynthia J. Tifft","orcid":"0000-0002-3931-1207","position":16,"is_corresponding":false},{"id":260096,"name":"Camilo Toro","orcid":"0000-0002-3917-9031","position":17,"is_corresponding":false},{"id":388993,"name":"Négar Khanlou","orcid":"0000-0002-7308-9363","position":18,"is_corresponding":false},{"id":70654,"name":"William A. Gahl","orcid":"0000-0002-2494-6752","position":19,"is_corresponding":false},{"id":397177,"name":"Noriko Salamon","orcid":"0000-0002-3520-9467","position":20,"is_corresponding":false},{"id":689560,"name":"Tyler Mark Pierson","orcid":"0000-0003-1985-3671","position":21,"is_corresponding":false},{"id":477740,"name":"María Gabriela Otero","orcid":"0000-0001-6263-2466","position":0,"is_corresponding":true}],"reference_count":97,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T02:08:10.215754Z","pmid":"38352418","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}